Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents, 2026-2027: Technical Report.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 42683687.
- Also identified by DOI 10.1542/peds.2026-079046.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This technical report accompanies the American Academy of Pediatrics policy statement recommendations for COVID-19 vaccination during the 2026-2027 respiratory virus season. The rationale is presented for recommending vaccination in all infants and children 6 through 23 months of age, children 6 months through 18 years of age who are moderately or severely immunocompromised, and children 2 through 18 years of age in certain additional risk groups, including those at high risk of severe COVID-19, residents of long-term care facilities or other congregate settings, children who have never been vaccinated against COVID-19, and children whose household contacts are at high risk for severe COVID-19. The report synthesizes currently available evidence on SARS-CoV-2 epidemiology, disease burden, COVID-19 vaccine effectiveness, vaccine safety, and vaccine cost-effectiveness in pediatric populations. Additionally, the report provides an overview of available COVID-19 vaccine products, formulations, storage and handling considerations, and coadministration with other immunizations.